Clo­vis On­col­o­gy her­alds a PARP vic­to­ry in front­line ovar­i­an can­cer — does any­one re­al­ly care much?

Ear­ly on Thurs­day, Clo­vis On­col­o­gy trum­pet­ed pos­i­tive Phase III da­ta for their PARP play­er Rubra­ca in front­line main­te­nance care of ovar­i­an can­cer, out­lin­ing a much im­proved PFS rate com­pared to place­bo.

The small-cap stock price $CLVS, which was evis­cer­at­ed and rel­e­gat­ed to Wall Street sideshow long ago, spiked 52%. That raised a cheer from the re­main­ing faith­ful who have seen the stock tank 95% over the last 5 years, as Clo­vis has strug­gled to find its way as the third PARP play­ing against ma­jor league ri­vals at As­traZeneca — the dom­i­nant pi­o­neer — and GSK, which saw their PARP ac­qui­si­tion as a key part of its new on­col­o­gy strat­e­gy.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE